Carregant...
Carfilzomib reverses pulmonary arterial hypertension
AIMS: Pulmonary arterial hypertension (PAH) remains a lethal disease with pronounced narrowing of pulmonary vessels due to abnormal cell growth. Agents that can reduce the pulmonary vascular thickness thus have therapeutic potential. The present study investigated the efficacy of carfilzomib (CFZ),...
Guardat en:
| Publicat a: | Cardiovasc Res |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4836627/ https://ncbi.nlm.nih.gov/pubmed/26952044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvw047 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|